Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

News SummaryMost relevantAll newsSector newsTweets 

Celgene Corporation : to Webcast at Upcoming Investor Conferences and Analyst Day

share with twitter share with LinkedIn share with facebook
share via e-mail
04/29/2013 | 02:40pm CEST

Celgene Corporation (NASDAQ: CELG) plans to present at four upcoming investor conferences in May. The conferences will be webcast live and the webcasts will be available in the Investor Relations section of the Company's website at www.celgene.com. Celgene management will provide an overview of the Company.

Thursday, May 9, 2013 Celgene will present at Baird's 2013 Growth Stock Conference at 1:20 p.m. ET.

Thursday, May 16, 2013 Celgene will present at the 2013 Bank of America Merrill Lynch Global Healthcare Conference at 12:20 p.m. ET.

Wednesday, May 22, 2013 Celgene will present at the 2013 UBS Global Healthcare Conference at 11:30 a.m. ET.

Thursday, May 30, 2013 Celgene will present at Sanford C. Bernstein's 29th Annual Strategic Decisions Conference at 9:00 a.m. ET.

Additionally, Celgene plans to host an Analyst and Institutional Investor Day on May 6. The presentation will be webcast beginning at 1 p.m. ET and is expected to conclude at 5 p.m.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the company's Web site at www.celgene.com.

Forward-Looking Statements

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

Celgene Corporation
Jacqualyn A. Fouse, Ph.D., 908-673-9956
EVP, Chief Financial Officer
Patrick E. Flanigan III, 908-673-9969
VP, Investor Relations

© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
01:14p CELGENE CORPORATION (NASDAQ : CELG) Cambridge Expansion Drive Gathers Momentum
04/20 CELGENE : FORMA Therapeutics Delivers Two Key Objectives in Collaboration with C..
04/20 CELGENE : Study Results from J.Q. Tran and Colleagues Update Understanding of Gl..
04/20 CELGENE : in Asia-Pacific collab with Antengene, Tigermed as clinical support
04/19 JUNO THERAPEUTICS, INC. (NASDAQ : JUNO) Files An 8-K Departure of Directors or C..
04/19 Celgene, Ionis ink China drug development pacts; Motif touts positive PhIII a..
04/13 CELGENE : Notified of ANDA Filing for POMALYST®
04/13 DIPLOMAT PHARMACY,INC. (NYSE : DPLO) Files An 8-K Entry into a Material Definiti..
04/11 ONCOMED PHARMACEUTICALS : OncoMeds Phase 2 Demcizumab Pancreatic Cancer Trial Mi..
04/06 CELGENE : Patent Issued for Besylate Salt of a BTK Inhibitor (USPTO 9604936)
More news
Sector news : Bio Therapeutic Drugs
04/18 Johnson & Johnson first quarter revenue misses estimates; new forecast includ..
04/18DJACTELION : J&J Lifts Forecast on Actelion Tie-Up--Update
04/18DJJOHNSON & JOHNSON : Lifts Forecast on Actelion Tie-Up
04/14DJELI LILLY AND : FDA Rejects Eli Lilly and Incyte Rheumatoid-Arthritis Drug -- Up..
04/14DJELI LILLY AND : FDA Rejects Eli Lilly and Incyte Rheumatoid-Arthritis Drug
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
04/23 WEEK IN REVIEW : Tianjin CanSino Closes $65 Million Round For Vaccine Portfolio
04/20 AGIOS : Another Core Biotech Buy Worth Picking Up
04/19 CELGENE : The Next Dominant Pharma Company
04/19 Gilead Sciences Near 3-Year Low. Time To Buy?
04/18 The Concentrated Portfolio
Financials ($)
Sales 2017 13 263 M
EBIT 2017 7 450 M
Net income 2017 4 560 M
Debt 2017 2 267 M
Yield 2017 -
P/E ratio 2017 21,53
P/E ratio 2018 17,20
EV / Sales 2017 7,34x
EV / Sales 2018 6,09x
Capitalization 95 114 M
More Financials
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Full-screen chart
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 141 $
Spread / Average Target 15%
Consensus details
EPS Revisions
More Estimates Revisions
Mark J. Alles Chief Executive Officer & Director
Scott Andrew Smith President & Chief Operating Officer
Robert J. Hugin Executive Chairman
Peter N. Kellogg Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN, INC.9.71%118 044
ACTELION LTD26.98%30 294
More Results